Trop2 deal heats up antibody–drug conjugate space in cancer thumbnail

Trop2 deal heats up antibody–drug conjugate space in cancer

Gilead’s $21 billion gamble is a dramatic shot to secure a promising first-in-class oncology drug.

Access options

Subscribe to Journal

Get full journal access for 1 year

$259.00

only $21.58 per issue

All prices are NET prices.

VAT will be added later in the checkout.

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

Author information

Affiliations

  1. Ann Arbor, MI, USA

    Catherine Shaffer

Authors

  1. Catherine Shaffer

    You can also search for this author in
    PubMed Google Scholar

About this article

Verify currency and authenticity via CrossMark

Cite this article

Shaffer, C. Trop2 deal heats up antibody–drug conjugate space in cancer.
Nat Biotechnol 39, 128–130 (2021). https://doi.org/10.1038/s41587-021-00824-8

Download citation

Read More

Leave a Reply

Your email address will not be published. Required fields are marked *